Japan’s regenerative medicine sector has encountered major challenges, underscored by the recent failures of products such as HeartSheet and Collategene. These setbacks expose critical weaknesses in the fast-track approval system, raising concerns about patient safety and the scientific robustness of product evaluations. Despite strong governmental support, addressing these fundamental issues is essential for the future success of regenerative medicine in Japan.
Get full access to this article
View all access options for this article.
References
1.
SawaY, YoshikawaY, TodaK, et al.Regeneration of the heart using a novel scaffold. Circ J, 2015; 79:991–999; doi: 10.1253/circj.CJ-15-0243
2.
Editorial. Ethical considerations in regenerative medicine research. Nature, 2015; 528:163–164; doi: 10.1038/528163b
3.
CyranoskiD. Regulatory hurdles for stem cell therapies in Asia. Nat Med, 2013; 19:510; doi: 10.1038/nm0513-510
4.
HonmouO, OnoderaR, SasakiM, et al.Stem cell therapy for stroke: A long-term clinical study. Clin Neurol Neurosurg, 2021; 203:106565; doi: 10.1016/j.clineuro.2021.106565
Editorial. Ethical lapses in clinical trials for stem cell therapies. Nature, 2019; 565:535–536; doi: 10.1038/d41586-019-00332-5
7.
MiyamotoS. The challenge of building public trust in stem cell research. Nature, 2019; 569:40; doi: 10.1038/d41586-019-01364-7
8.
SippD, CaulfieldT, KayeJ. Navigating the future of regenerative medicine regulation. Science, 2019; 365:644–646; doi: 10.1126/science.aax6184
9.
OchiM, UchioY, KawasakiK, et al.Repair of cartilage defects with autologous chondrocytes in clinical practice. J Bone Joint Surg Br, 2002; 84:571–578; doi: 10.1302/0301-620X.84B4.0840571
